Urogen Pharma Ltd
URGN19.530USD
+0.130+0.67%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
824.79MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Urogen Pharma Ltd Unternehmen
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Unternehmensinformationen
BörsenkürzelURGN
Name des UnternehmensUrogen Pharma Ltd
IPO-datumMay 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
Anzahl der mitarbeiter235
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
Addresse9 Ha'ta'asiya St
StadtRA'ANANA
BörseNASDAQ Global Market Consolidated
LandIsrael
Postleitzahl4365007
Telefon97297707601
Websitehttps://www.urogen.com/
BörsenkürzelURGN
IPO-datumMay 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
41.49K
+27.61%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
41.49K
+27.61%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Jelmyto
20.25M
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Jelmyto
20.25M
0.00%
Aktionärsstatistik
Aktualisiert: Sun, Jul 27
Aktualisiert: Sun, Jul 27
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
8.30%
RA Capital Management, LP
6.94%
TD Securities, Inc.
6.91%
UBS Asset Management (Switzerland)
5.71%
Soleus Capital Management, L.P.
5.03%
Other
67.11%
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
8.30%
RA Capital Management, LP
6.94%
TD Securities, Inc.
6.91%
UBS Asset Management (Switzerland)
5.71%
Soleus Capital Management, L.P.
5.03%
Other
67.11%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
28.01%
Investment Advisor/Hedge Fund
23.81%
Hedge Fund
22.04%
Research Firm
10.69%
Venture Capital
10.21%
Insurance Company
6.72%
Corporation
4.78%
Bank and Trust
2.45%
Individual Investor
2.08%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
285
52.24M
113.07%
+4.72M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
2023Q1
221
19.00M
81.20%
-1.17M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RTW Investments L.P.
3.83M
8.32%
--
--
Mar 31, 2025
RA Capital Management, LP
3.21M
6.95%
+3.21M
--
Mar 31, 2025
TD Securities, Inc.
2.65M
5.75%
+903.36K
+51.65%
Jun 09, 2025
UBS Asset Management (Switzerland)
2.64M
5.73%
+1.28M
+94.68%
Mar 31, 2025
Soleus Capital Management, L.P.
2.33M
5.04%
+2.33M
--
Jun 13, 2025
Menora Mivtachim Insurance Ltd.
2.30M
4.99%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.15M
4.67%
+522.96K
+32.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.65%
-50.01K
-2.28%
Mar 31, 2025
UBS Asset Management (Americas) LLC
1.72M
3.73%
+1.72M
--
Mar 31, 2025
Acorn Capital Advisors, LLC
1.52M
3.29%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ARK Israel Innovative Technology ETF
1.96%
Hypatia Women CEO ETF
1.9%
ALPS Medical Breakthroughs ETF
0.43%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Biotechnology ETF
0.06%
iShares Russell 2000 Growth ETF
0.03%
SPDR S&P International Small Cap ETF
0.03%
Global X Russell 2000 ETF
0.02%
Mehr Anzeigen
ARK Israel Innovative Technology ETF
Anteil1.96%
Hypatia Women CEO ETF
Anteil1.9%
ALPS Medical Breakthroughs ETF
Anteil0.43%
iShares Micro-Cap ETF
Anteil0.11%
ProShares Ultra Nasdaq Biotechnology
Anteil0.07%
Invesco Nasdaq Biotechnology ETF
Anteil0.07%
iShares Biotechnology ETF
Anteil0.06%
iShares Russell 2000 Growth ETF
Anteil0.03%
SPDR S&P International Small Cap ETF
Anteil0.03%
Global X Russell 2000 ETF
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
